Keywords
Lupus nephritis
Class V lupus nephritis
Submitted : 2024-04-10
Accepted : 2024-04-25
Published : 2024-05-10
Abstract
Membranous lupus nephritis (MLN), class V, is a distinct LN characterized by immune complex deposition on subepithelial kidney biopsy. MLN is often associated with nephrotic syndrome. The histology of MLN is very similar to idiopathic (primary) membranous nephropathy (pMN). However, MLN usually has abundant mesa-glomerular deposits absent in primary membranous nephropathy. The clinical manifestations, management, and prognosis of MLN differ from other types of LN (type III, IV, or mixed type III/IV + V). Although immunosuppressive therapy is often necessary for MLN, the optimal treatment regimen is yet to be determined. This review summarizes the progress in the diagnosis and treatment of MLN and discusses the selection of immunosuppressants for MLN.
References
Xiong Q, 2006, Clinical Experience Treating Systemic Lupus Erythematosus with Integrated Traditional Chinese and Western Medicine. Henan Journal of Traditional Chinese Medicine, 26(2): 32–33.
Ye R, 2003, Nephrology of Integrative Traditional Chinese and Western Medicine, People’s Medical Publishing House, Beijing, 254 + 258–261.
Bertsias GK, Tektonidou M, Amoura Z, et al., 2012, Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR ERA-EDTA) Recommendations for Managing Adult and Pediatric Lupus Nephritis. Ann Rheum Dis, 71(11): 1771–1782.
Zeng H, Sun S, 2015, European Guidelines for the Management of Lupus Nephritis. Journal of Internal Medicine and Intensive Care, 21: 241–244.
Fu P, Qin W, 2012, Interpretation of KDIGO Guidelines: Treatment of Lupus Nephritis, Chinese Journal of Practical Medicine, 12: 921–924.
Appel GB, Contreras G, Dooley MA, et al., 2009, Mycophenolate Mofetil Versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. J Am Soc Nephrol, 20(5): 1103–1112.
Weng J, Lai P, Lv M, et al., 2013, Bortezomib Modulates Regulatory T Cell Subpopulations in Acute Graft-VersusHostDisease. Clin Lab 59(1–2): 51–58.
Gallagher KM, Lauder S, Rees IW, et al., 2009, Type I Interferon (IFN Alpha) Acts Directly on Human Memory CD4+T Cells Altering Their Response to Antigen. J Immunol, 183(5): 2915–2920.
Jego G, Palucka AK, Blanck JP, et al., 2003, Plasmacytoid Dendritic Cells Induce Plasma Cell Differentiation Through Type I Interferon and Interleukin 6. Immunity 19(2): 225–234.
Rönnblom L, Alm GV, Eloranta ML, 2011, The Type I Interferon System in the Development of Lupus. Semin Immunol, 23(2): 113–121.
Austin HAI 3rd, Klippel JH, Balow JE, et al., 1986, Therapy of Lupus Nephritis. Controlled Trial of Prednisone and Cytotoxic Drugs. N Engl J Med 314(10): 614–619.
Vollmer TL, Sorensen PS, Selmaj K, et al., 2014, BRAVO Study Group: A Randomized Placebo-Controlled Phase III Trial of Oral Laquinimod for Multiple Sclerosis. J Neurol 261(4): 773–783.
Lourenço EV, Wong M, Hahn BH, et al., 2014, Laquinimod Delays and Suppresses Nephritis in Lupus-Prone Mice, Affecting Myeloid and Lymphoid Immune Cells. Arthritis Rheumatol, 66(3): 674–685.
Jayne D, Appel G, Chan TM, et al., 2013, The Pharmacokinetics of Laquinimod and Mycophenolate Mofetil During Treatment of Active Lupus Nephritis. Proceedings of the 2013 American Society of Nephrology Annual Meeting.
Shen P, 1997, Clinical Research on the Treatment of Lupus Erythematosus with Traditional Chinese Medicine, People’s Health Publishing House, Beijing.
Ye R, Ren G, Li H, et al., 1994, Observation on Curative Effect of 74 Cases of Lupus Nephritis Treated with Integrated Traditional Chinese and Western Medicine. Journal of Integrated Traditional Chinese and Western Medicine, 14(6): 343.